Resverlogix is a clinical-stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is currently developing RVX-208, which is a first-in-class small molecule for treating atherosclerosis and the first BET bromodomain inhibitor in clinical trials. New compounds resulting from the company’s epigenetic drug discovery platform, which function by inhibiting BET bromodomains, have the potential to impact multiple diseases, including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. For more information, visit the company’s Web site at www.resverlogix.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: